Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (ITP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03201848
Recruitment Status : Recruiting
First Posted : June 28, 2017
Last Update Posted : June 28, 2022
Sponsor:
Collaborator:
Huazhong University of Science and Technology
Information provided by (Responsible Party):
Qidong Gaitianli Medicines Co., Ltd

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of Huaiqihuang granule for treatment to children with chronic primary immune thrombocytopenia (Qi Yin deficiency).

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia Drug: Placebo Drug: Huaiqihuang Granule Phase 4

Detailed Description:

The randomized clinical trial included subjects (n =216) will be randomly divided into experimental (n = 162) and control groups (n =54) according to a random number table. Patients in the experimental group will receive Huaiqihuang Granule . Patients in the control group will receive placebo a placebo-controlled designed is used for this study. To minimize the risks, treatment stopping rules and subsequent measures are established for subjects whose disease under study become worsening during the study. Subjects receiving placebo treatment will switch to investigational drug after Week 24 to reduce the risk of lack of efficacy by placebo.

The primary outcome measures is proportion of patients whose hemorrhage has improved (clinical effective rate).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency)
Actual Study Start Date : November 16, 2017
Estimated Primary Completion Date : December 3, 2022
Estimated Study Completion Date : March 3, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Huaiqihuang Granule
Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
 Drug: Huaiqihuang Granule
Huaiqihuang Granule given to subject will be adjusted by body weight (<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
Other Name: Huaiqihuang
Placebo Comparator: Placebo
Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
 Drug: Placebo
Placebo given to subject will be adjusted by body weight (<10kg, Placebo given to subject will be adjusted by body weight(<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .

Drug: Huaiqihuang Granule
Huaiqihuang Granule given to subject will be adjusted by body weight (<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
Other Name: Huaiqihuang


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. the proportion of subjects whose hemorrhage has improved (clinical effective rate) [ Time Frame: 24、48 and 60 Weeks after treatment ]

    The improvement of hemorrhage is defined if at least one of the following criteria is met:

    1. Severity of hemorrhage decreases one or more grade, the severity of hemorrhage is defined as following: none: there is any hemorrhage manifestation; mild: simple (often related with an unnoticeable minor collision without obvious ecchymosis) or obvious ecchymosis by collision; moderate: mucous membrane hemorrhage (nose hemorrhage, gum, oral mucosa) and menorrhagia; and severe: organ hemorrhage (digestive tract, respiratory tract, intracranial, etc.).
    2. Significant increase in platelet count defined as platelet count is over 30×109/L and increases more than twice compared with the baseline. The results must be tested at least twice with at least 7 days apart).
    3. The score of quality of life improves one or more points.


Secondary Outcome Measures :
  1. the recovery rate of immune function [ Time Frame: 24、48 and 60 Weeks after treatment ]
    The recovery rate of immune function is the proportion of subjects who have normalized immune function after treatment. The parameters of immune function include cytokines, lymphocyte subsets and auto immunity. One of the three tests has been restored to normal is defined as the immune function has returned to normal.

  2. the recovery rate of thyroid function [ Time Frame: 12、24、36、48、60 and 72 Weeks after treatment ]
    The recovery rate of thyroid function is the proportion of subjects who have normalized immune function after treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, aged between 1 and 14 years (inclusive) ;
  2. Is diagnosed as immune thrombocytopenia according to the criteria of ICD-10, i.e., platelet < 100×109/L for at least two hematology tests with normal blood cell morphology; skin petechia, ecchymosis and (or) the clinical manifestations of mucosa and visceral hemorrhage; no splenomegaly; exclusion of other secondary thrombocytopenia, such as aplastic leukemia, aplastic anemia characterized by thrombocytopenia as the first hematologic abnormality, hereditary thrombocytopenia, thrombocytopenia secondary to other autoimmune diseases, infections or drugs etc...
  3. Meet the diagnosis criteria for Qi Yin deficiency in traditional Chinese medicine;
  4. Time since initial diagnosis of ITP until randomization is at least 12 month, i.e., course of disease ≥1 year;
  5. Values of prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) are within 1.2 times of normal reference range;
  6. Values of biochemistry parameters including creatinine, ALT, AST, glucose, total bilirubin are less than 1.2 time of the corresponding upper limit of normal range;
  7. Has signed and dated the informed consent in volunteer by the subject and the subject's legal guardian(s) (for subject who is less than 8 years old, the informed consent will be signed and dated by the subject's legal guardian(s) in volunteer).

Exclusion Criteria:

  1. Is diagnosed as congenital thrombocytopenia;
  2. Is diagnosed as secondary thrombocytopenia;
  3. Is diagnosed as non-immune thrombocytopenia;
  4. Has medical history of diabetes;
  5. In the judgement of Investigator, the subject is not appropriate to participate in this study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03201848


Contacts
Layout table for location contacts
Contact: Yonghui Lu, Ph.D +0086-13801462500 lyh307@sina.com

Locations
Layout table for location information
China, Guangdong
Guangzhou Women and Children's Medical Center Recruiting
Guangzhou, Guangdong, China
Contact: Hua Jiang         
The First Affiliated Hospital, Sun Yat-sen University Recruiting
Guangzhou, Guangdong, China
Contact: Xuequn Luo         
China, Henan
The First Affiliated Hospital of Zhengzhou University Recruiting
Zhengzhou, Henan, China
Contact: Yufeng Liu         
China, Hubei
Union Hospital of Tongji Medical College, Huazhong University of Science & Technology Recruiting
Wuhan, Hubei, China, 430022
Contact: runming jin, Professor    +0086-13037111958    jinrunm@qq.com   
Wuhan Children's Hospital Recruiting
Wuhan, Hubei, China
Contact: Jianxin Li         
China, Jiangsu
Children's Hospital of Nanjing Medical University Recruiting
Nanjing, Jiangsu, China
Contact: Yongjun Fang         
Children's Hospital of Soochow University Recruiting
Suzhou, Jiangsu, China
Contact: Jianqin Li         
China, Jiangxi
Jiangxi Provincial Children's Hospital Recruiting
Nanchang, Jiangxi, China
Contact: Changda Liang         
China, Shandong
The Affiliated Hospital of Qingdao University Recruiting
Qingdao, Shandong, China
Contact: Lirong Sun         
China, Sichuan
The Affiliated Hospital of Southwest Medical University Recruiting
Luzhou, Sichuan, China
Contact: Wenjun Liu         
China, Xinjiang
First Affiliated Hospital of Xinjiang Medical University Recruiting
Ürümqi, Xinjiang, China
Contact: Mei Yan         
China
Beijing Children's Hospital. Capital Medical University Recruiting
Beijing, China
Contact: Runhui Wu         
Children's Hospital Capital Institute of Pediatrics Recruiting
Beijing, China
Contact: Xiaodong Shi         
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Recruiting
Shanghai, China
Contact: Xiaojun Yuan         
Sponsors and Collaborators
Qidong Gaitianli Medicines Co., Ltd
Huazhong University of Science and Technology
Investigators
Layout table for investigator information
Principal Investigator: Runming Jin, Professor Wuhan Union Hospital, China
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Qidong Gaitianli Medicines Co., Ltd
ClinicalTrials.gov Identifier: NCT03201848    
Other Study ID Numbers: HQH-201703.01
First Posted: June 28, 2017    Key Record Dates
Last Update Posted: June 28, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Qidong Gaitianli Medicines Co., Ltd:
Huaiqihuang granule
immune thrombocytopenia
randomized
double-blind
placebo-controlled,
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Purpura
Blood Coagulation Disorders
 Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations